PDX/O oncology platform developments at InnoSer

PDX/O oncology platform developments at InnoSer

Apr 7, 2020

Despite the challenging times for the life sciences sector during coronavirus restrictions, we’ve been fortunate enough and well prepared to continue with the development of our PDX/O platform for oncology research. On a weekly basis we receive patient tumor samples...
Taking Precautions Against Coronavirus

Taking Precautions Against Coronavirus

Mar 13, 2020

Following the most recent governmental advice and regulations, we have decided to take preventative measures against the fast spread of COVID-19. The health and interests of our customers, employees and other stakeholders are our top priority. In order to minimize the...
InnoSer and OrganoTherapeutics to Offer Midbrain Organoids

InnoSer and OrganoTherapeutics to Offer Midbrain Organoids

Feb 10, 2020

InnoSer is joining forces with OrganoTherapeutics to make midbrain organoids available for screening and development of pharmaceutical compounds. This partnership will enable providing midbrain organoids commercially as a platform for Parkinson’s disease research. CEO...

InnoSer and TheraIndx Strategic Partnership

Jan 31, 2020

InnoSer and TheraIndx announce their strategic partnership to better serve pharmaceutical and biomedical companies worldwide. Jan Bartels, the CEO of InnoSer, states: “Both companies offer unique service portfolios and bring a lot of aligned added value to our global...

InnoSer gets new cell culture facilities

Jan 31, 2020

InnoSer is expanding its infrastructure to better its in vitro services. These specialized services include syngeneic oncology models, PBMC and immune population work in vitro/ex vivo, organoid culture, PDX passage work and any in vitro compound screening on fresh...